Shingrix is over 90% effective against shingles in older adults, vastly superior to the previous vaccine and safe for immunocompromised patients including HIV-positive individuals. Emerging evidence from UK and US data suggests shingles vaccination may reduce dementia risk by approximately 20-24%, potentially through preventing brain blood vessel inflammation.
TimesLIVE
· Jul 16, 2026
· health
· 7 min de lectura
High
Verificación: Caracterizado
New shingles vaccine shows dementia protection promise, but South Africa faces affordability hurdles
◉
Health & Medicine
8951 artículos relacionados
FDA Approves Pancreatic Cancer Drug That May Extend Patient Survival
CBS News · 100% coincidencia
DRC Enrolls First Patient in Ebola Treatment Trial Amid Outbreak
98.4 Capital FM Kenya · 99% coincidencia
GSK's RSV vaccine Arexvy approved for high-risk adults aged 18-49 in K…
koreabiomed.com · 99% coincidencia
Congo's Rare Ebola Strain Spreads Undetected as Scientists Race to Dev…
Hindustan Times · 99% coincidencia
Three vaccine candidates fast-tracked for rare Bundibugyo Ebola strain…
News18 · 99% coincidencia
Cobertura Relacionada
BBC News · Sep 04
UK new-build crisis: defects, mould force families from homes as ombudsman complaints triple
Dozens of UK homebuyers report serious defects in new-build properties including mould, structural issues, and damp. Com…
The Guardian · Sep 04 New Zealand becomes second nation to approve MDMA for severe PTSD treatmentNew Zealand's Medsafe approved two psychiatrists to prescribe pharmaceutical-grade MDMA for severe PTSD, making it only …
Insurance Business · Sep 04 Intact Insurance Defeats Chronic Pain Claim Under Ontario's Minor Injury CapA Licence Appeal Tribunal rejected a claimant's attempt to exceed Ontario's $3,500 minor injury cap following a 2023 car…
News-Medical · Sep 04 Study identifies how prednisone impairs bone health in children with muscular dystrophyResearch identifies blood proteins explaining how prednisone, while treating Duchenne muscular dystrophy, impairs childh…
Sesgo y Encuadre
⚖
Article presents Shingrix vaccine benefits with balanced acknowledgment of affordability barriers in South Africa, using personal narrative framing to illustrate real-world impact.
Bias Direction
center
Confidence
MED
Human-interest narrative combined with health education. Opens with personal anecdote (Verwoerd's experience) to create emotional engagement, then transitions to factual health information and economic barriers. Frames the vaccine as both solution and accessibility challenge.
eye-watering price
angry blisters
pain like nothing she'd experienced before
steep price
sharper mind in old age
Healthcare economists' analysis of cost-benefit ratios
Public health officials' prioritization rationale for vaccine rollout
Voices of lower-income South Africans who cannot afford the vaccine
Alternative or complementary preventive approaches
GSK's justification for pricing strategy beyond manufacturer statement
Comparative international pricing data
Impacto Geopolítico
🌎
South Africa's introduction of Shingrix vaccine offers dementia protection but faces adoption barriers due to high cost (R5,566) and low vaccination culture, with limited geopolitical implications.
Escalation Risk
low
Confidence
MED
South Africa
Sub-Saharan Africa
Global pharmaceutical markets
GSK maintains pricing control in emerging markets; South Africa's healthcare system faces pressure to subsidize or negotiate prices; potential influence on regional vaccine adoption patterns in SADC countries.
Similar to HPV vaccine rollout challenges in developing nations where efficacy benefits competed against affordability barriers and public health infrastructure limitations.
Lente Económico
📈
South Africa's Shingrix vaccine launch offers dementia protection but faces affordability barriers at R5,566 for full course, limiting adoption in price-sensitive market with low adult vaccination rates.
Market Signal
mixed
Confidence
HIGH
Healthcare/Pharmaceuticals
Public Health
Medical Insurance
Geriatric Care
Medical Device Distribution
Consumers face high out-of-pocket costs (R5,566) for preventive vaccine with dual benefits, likely limiting uptake to affluent segments. Low-income households unable to afford protection against shingles and potential dementia risk reduction, widening healthcare inequality.
Government may need to consider Shingrix inclusion in public health programs or negotiate price reductions with GSK to improve accessibility. Potential regulatory review of vaccine pricing; possible insurance coverage mandates to improve adoption rates and reduce long-term dementia-related healthcare costs.